Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stent showdown: can covered stents beat bare metal for kidney artery blockages?

NCT ID NCT07566065

Disease control Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether covered stents are better than bare metal stents for people with narrowed kidney arteries caused by atherosclerosis. About 150 participants will be randomly assigned to one stent type and followed for 12 months to see changes in kidney function and blood pressure. The goal is to find the best way to treat this condition and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
covered stent (device) and bare metal stent (device)
What this could lead to
If covered stents prove better, this could become the preferred treatment for renal artery stenosis, helping control blood pressure and protect kidney function.
What could go wrong
This is a relatively small, early-stage study with only 150 participants, and results may not apply to all patients. Stent procedures carry risks like vessel damage or restenosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) Renal artery diameter stenosis ≥60%; 2) Office systolic blood pressure ≥ 160 mmHg and/or office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and/or office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses; 3) Serum creatinine \< 264 μmol/L (3.0 mg/dL); 4) Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL/min; Exclusion Criteria: * 1\) Unstable clinical condition rendering the patient intolerant to revascularisation therapy; 2) Urinary protein ≥2+; 3) Contrast medium allergy; 4) Renal artery anatomy unsuitable for revascularisation therapy; 5) Reference vessel diameter \<3.5mm or \>8mm. 6)Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis); 7)Reference vessel diameter \< 3.5 mm or \> 8 mm

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic renal artery stenosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder renal artery atheroma renal artery disease renal artery obstruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic renal artery stenosis Hypertension Renal artery stenosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affilated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, 116001, China

  • China-Japan Union Hospital of Jilin University, Changchun, Lilin

    Jilin City, 130033, China

  • Department of Cardiovascular Medicine, Cardiovascular Research Center , The First Affiliated Hospital of Chongqing Medical University

    Chongqing, 400016, China

  • Frist Aiffiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Fuwai Central China Cardiovascular Hospital

    Zhengzhou, Henan, 450000, China

  • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037

    Beijing, China

  • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)

    Nanchang, Jiangxi, 330038, China

  • Nanjing Pukou People's Hospital(Liangjiang Hospital Southeast University)

    Nanjing, Jiangsu, 211800, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

  • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)

    Qingdao, Shandong, China

  • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu

    Chengdu, Sichuan, 610031, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510000, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150086, China

  • The Second Affiliated Hospital of Harbin Medical University, Ha'erbin

    Harbin, China

  • Zhengzhou Central Hospital Affiliated to Zhengzhou University

    Zhengzhou, Henan, 450007, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.